<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04027439</url>
  </required_header>
  <id_info>
    <org_study_id>RPL554-DP-201</org_study_id>
    <nct_id>NCT04027439</nct_id>
  </id_info>
  <brief_title>Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler</brief_title>
  <official_title>A Phase II, Randomized Study to Assess the Pharmacokinetics, Safety and Pharmacodynamics of Single and Repeat Doses of RPL554 Administered by Dry Powdered Inhaler in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verona Pharma plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Verona Pharma plc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate 5 doses of RPL554 and placebo, administered by&#xD;
      dry powder inhaler (DPI), in patients with moderate to severe chronic obstructive pulmonary&#xD;
      disease (COPD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of two parts. Part A is a parallel group, placebo-controlled single&#xD;
      dose study to ascertain the Pharmacokinetics (PK) profile, safety and bronchodilator effect&#xD;
      of RPL554 administered via dry powder inhaler (DPI). Five of the 6 treatment arms will be&#xD;
      double-blind and one will be single-blind (due to the different number of capsules&#xD;
      administered). Part B is a placebo-controlled, complete block cross-over, repeat dose study&#xD;
      to assess the bronchodilator effect of repeat doses of RPL554 delivered via a DPI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Actual">May 23, 2019</completion_date>
  <primary_completion_date type="Actual">May 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12)</measure>
    <time_frame>Day 1</time_frame>
    <description>RPL554 Plasma pharmacokinetics AUC0-12 (Area under the Curve) after single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t)</measure>
    <time_frame>Day 1</time_frame>
    <description>RPL554 Area under the curve at maximum concentration after a single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life)</measure>
    <time_frame>Day 1</time_frame>
    <description>RPL554 Plasma pharmacokinetics Half-life concentration after a single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from Baseline FEV1 to Peak FEV1 (over 4 hours) on Day 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Change From Baseline in Average FEV1 (Over 4 Hours)</measure>
    <time_frame>Day 1</time_frame>
    <description>Change from Baseline FEV1 to Average FEV1 (over 4 hours) After Single Dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change From Baseline in Average FEV1 (Over 12 Hours)</measure>
    <time_frame>Day 1</time_frame>
    <description>Change from Baseline FEV1 to Average FEV1 (over 12 hours) After Single Dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change From Baseline in Peak FEV1 (Over 4 Hours)</measure>
    <time_frame>Day 1</time_frame>
    <description>Change from Baseline FEV1 to Peak FEV1 (over 4 hours) After Single Dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and Tolerability / Hematology Safety Assessments</measure>
    <time_frame>Day 1</time_frame>
    <description>number of patients with treatment-emergent hematology abnormal laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and Tolerability / Blood Chemistry Safety Assessments</measure>
    <time_frame>Day 1</time_frame>
    <description>number of patients with treatment-emergent blood chemistry abnormal laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and Tolerability / Urinalysis Safety Assessments</measure>
    <time_frame>Day 1</time_frame>
    <description>number of patients with treatment-emergent urinalysis abnormal laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and Tolerability / Supine Vital Signs - Pulse Rate</measure>
    <time_frame>Day 1</time_frame>
    <description>Change from Baseline Pulse Rate to Peak Pulse Rate (over 4 hours) After Single Dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and Tolerability / Supine Vital Signs - Blood Pressure</measure>
    <time_frame>Day 1</time_frame>
    <description>number of patients with treatment-emergent abnormal vital signs (blood pressure in mm Hg) (An increase from baseline of &gt;=20 in systolic bp)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and Tolerability / ECG - QTcF</measure>
    <time_frame>Day 1</time_frame>
    <description>number of patients with treatment-emergent abnormal ECG parameters, QTcF in msec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and Tolerability / ECG - Heart Rate</measure>
    <time_frame>Day 1</time_frame>
    <description>number of patients with treatment-emergent clinically significant abnormal ECG parameters, heart rate in bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Average FEV1 (Over 4 Hrs)</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in average FEV1 (over 4 hours) on Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Average FEV1 (Over 12 Hours)</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Trough FEV1</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from Baseline FEV1 to Morning Trough FEV1 on Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)</measure>
    <time_frame>Day 1</time_frame>
    <description>Change from baseline FEV1 in peak FEV1 (over 4 hours) after first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Average FEV1 (Over 4 Hours)</measure>
    <time_frame>Day 1</time_frame>
    <description>Change from baseline FEV1 in average FEV1 (over 4 hours) on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Average FEV1 (Over 12 Hours)</measure>
    <time_frame>Day 1</time_frame>
    <description>Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action)</measure>
    <time_frame>Day 1</time_frame>
    <description>Determination of onset of action (&gt;10% increase in FEV1 from pre- to post-first dose, censored at 120 minutes) on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety and Tolerability / Hematology Safety Assessments</measure>
    <time_frame>Day 7</time_frame>
    <description>number of patients with treatment-emergent hematology abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 or at the end of study in &gt;3 patients in each treatment group).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety and Tolerability / Blood Chemistry Safety Assessments</measure>
    <time_frame>Day 7</time_frame>
    <description>number of patients with treatment-emergent blood chemistry abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 in each treatment group).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety and Tolerability / Urinalysis Safety Assessments</measure>
    <time_frame>Day 7</time_frame>
    <description>number of patients with treatment-emergent urinalysis abnormal laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety and Tolerability / ECG - QTcF</measure>
    <time_frame>Day 7</time_frame>
    <description>number of patients with treatment-emergent clinically significant abnormal ECG parameters, QTcF in msec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety and Tolerability / ECG - Heart Rate</measure>
    <time_frame>Day 7</time_frame>
    <description>number of patients with treatment-emergent abnormal ECG parameters, heart rate in bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety and Tolerability / Supine Vital Signs - Pulse Rate</measure>
    <time_frame>Day 7</time_frame>
    <description>number of patients with treatment-emergent abnormal vital signs (pulse rate in bpm) An increase from baseline of &gt;=20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety and Tolerability / Supine Vital Signs - Blood Pressure</measure>
    <time_frame>Day 7</time_frame>
    <description>number of patients with treatment-emergent abnormal vital signs (systolic blood pressure in mm Hg) (An increase from baseline of &gt;=20)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Peak Pulse Rate (Day 1)</measure>
    <time_frame>Day 1</time_frame>
    <description>Change from baseline in peak pulse after first dose on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Peak Pulse Rate (Day 7)</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in peak pulse after morning dosing on Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: RPL554 Plasma Pharmacokinetic Parameter (Tmax)</measure>
    <time_frame>Day 7</time_frame>
    <description>RPL554 steady-state PK (tmax) after morning dose on Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: RPL554 Plasma Pharmacokinetic Parameter (Cmax)</measure>
    <time_frame>Day 7</time_frame>
    <description>RPL554 steady-state PK (Cmax and accumulation ratio) after morning dose on Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h)</measure>
    <time_frame>Day 7</time_frame>
    <description>RPL554 steady-state PK (AUC0-12h and accumulation ratio) after morning dose on Day 7</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Part A: RPL554</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo controlled, parallel group single dose. Five of the 6 treatment arms will be double-blind and one will be single-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: RPL554</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double-blind, placebo-controlled, complete block cross-over</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part A: RPL554</intervention_name>
    <description>1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler</description>
    <arm_group_label>Part A: RPL554</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part B: RPL554</intervention_name>
    <description>Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A</description>
    <arm_group_label>Part B: RPL554</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler.&#xD;
Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A.</description>
    <arm_group_label>Part A: RPL554</arm_group_label>
    <arm_group_label>Part B: RPL554</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign an informed consent document indicating they understand the purpose of and&#xD;
             procedures required for the study and are willing to participate in the study.&#xD;
&#xD;
          2. For males, not to donate sperm and either be sexually abstinent or use contraception&#xD;
             as specified by the protocol. For females, be of non-childbearing potential or use a&#xD;
             highly effective form of contraception&#xD;
&#xD;
          3. 12-lead ECG with heart rate between 45 and 90 beats per minute, QTcF ≤450 msec for&#xD;
             males, and ≤ 470 msec for females, QRS interval ≤120 msec and no clinically&#xD;
             significant abnormality including morphology&#xD;
&#xD;
          4. Capable of complying with all study restrictions and procedures including ability to&#xD;
             use the DPI correctly.&#xD;
&#xD;
          5. Body mass index (BMI) between 18 and 35 kg/m2 (inclusive) with a minimum weight of 45&#xD;
             kg.&#xD;
&#xD;
          6. COPD diagnosis for 1 year [prior to screening&#xD;
&#xD;
          7. Ability to perform acceptable and reproducible spirometry.&#xD;
&#xD;
          8. Post-bronchodilator (four puffs of albuterol) spirometry at Screening demonstrating&#xD;
             the following:&#xD;
&#xD;
               -  FEV1/Forced Vital Capacity (FVC) ratio of ≤0.70&#xD;
&#xD;
               -  FEV1 ≥40 % and ≤80% of predicted normal&#xD;
&#xD;
               -  ≥150 mL increase from pre-bronchodilator FEV1&#xD;
&#xD;
          9. Clinically stable COPD in the 4 weeks prior to Screening and during the period between&#xD;
             Screening and Part A.&#xD;
&#xD;
         10. A chest X-ray showing no abnormalities, which are both clinically significant and&#xD;
             unrelated to COPD.&#xD;
&#xD;
         11. Meet the concomitant medication restrictions and be expected to do so for the rest of&#xD;
             the study.&#xD;
&#xD;
         12. Current and former smokers with smoking history of ≥10 pack years. 14. Capable of&#xD;
             withdrawing from long acting bronchodilators for the duration of the study, and short&#xD;
             acting bronchodilators for 8 hours prior to dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A history of life-threatening COPD including Intensive Care Unit admission and/or&#xD;
             requiring intubation.&#xD;
&#xD;
          2. COPD exacerbation requiring oral or parenteral steroids, or lower respiratory tract&#xD;
             infection requiring antibiotics, within 3 months of Screening or prior to Part A.&#xD;
&#xD;
          3. A history of one or more hospitalizations for COPD or pneumonia within 6 months of&#xD;
             Screening or prior to Part A.&#xD;
&#xD;
          4. Intolerance or hypersensitivity to tiotropium, olodaterol, atropine, ipratropium, or&#xD;
             RPL554.&#xD;
&#xD;
          5. Evidence of cor pulmonale or clinically significant pulmonary hypertension.&#xD;
&#xD;
          6. Other respiratory disorders&#xD;
&#xD;
          7. Previous lung resection or lung reduction surgery.&#xD;
&#xD;
          8. Use of immunosuppressive therapy, including oral corticosteroids&#xD;
&#xD;
          9. Pulmonary rehabilitation, unless such treatment has been stable from 4 weeks prior to&#xD;
             Screening and remains stable during the study.&#xD;
&#xD;
         10. History of, or reason to believe a patient has, drug or alcohol abuse within the past&#xD;
             5 years.&#xD;
&#xD;
         11. Received an experimental drug within 30 days or five half lives, whichever is longer.&#xD;
&#xD;
         12. Patients with uncontrolled disease including, but not limited to, endocrine, active&#xD;
             hyperthyroidism, neurological, hepatic, gastrointestinal, renal, hematological,&#xD;
             urological, immunological, psychiatric, or ophthalmic diseases that the Investigator&#xD;
             believes are clinically significant.&#xD;
&#xD;
         13. Documented cardiovascular disease, including any history of arrhythmias, angina,&#xD;
             recent (&lt;1 year) or suspected myocardial infarction, congestive heart failure,&#xD;
             unstable or uncontrolled hypertension, or diagnosis of hypertension within 3 months&#xD;
             prior to Screening&#xD;
&#xD;
         14. Use of non-selective oral β-blockers.&#xD;
&#xD;
         15. Major surgery (requiring general anesthesia) within 6 weeks prior to Screening, lack&#xD;
             of full recovery from surgery at Screening, or planned surgery through the end of the&#xD;
             study.&#xD;
&#xD;
         16. A disclosed history or one known to the Investigator, of significant non compliance in&#xD;
             previous investigational studies or with prescribed medications.&#xD;
&#xD;
         17. Required use of oxygen therapy, even on an occasional basis.&#xD;
&#xD;
         18. History of malignancy of any organ system within 5 years, with the exception of&#xD;
             localized skin cancers (basal or squamous cell).&#xD;
&#xD;
         19. Clinically significant abnormal values for safety laboratory tests (hematology,&#xD;
             biochemistry, viral serology or urinalysis) at Screening, as determined by the&#xD;
             Investigator. In particular, alanine aminotransferase or aspartate aminotransferase&#xD;
             cannot be more than twice the upper limit of normal.&#xD;
&#xD;
         20. Any other reason that the Investigator considers makes the patient unsuitable to&#xD;
             participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Boscia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vitalink Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VitaLink Research -- Union</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 9, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2019</study_first_posted>
  <results_first_submitted>December 3, 2020</results_first_submitted>
  <results_first_submitted_qc>April 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2021</results_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT04027439/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT04027439/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>37 subjects enrolled for Part A and anticipated to continue into Part B.</recruitment_details>
      <pre_assignment_details>Part A: 37 Patients randomized equally to receive a single dose of RPL554 (0.15, 0.5, 1.5, 3, or 6 mg) or matching placebo via dry powder inhaler (DPI). Patients were to continue to Part B after Part A is complete.&#xD;
Part B: 35 Patients continued from Part A and randomly assigned to 1 of 10 treatment sequences in a crossover design (5 x 1-week treatment periods separated by 7-10 day washout). Each sequence included twice daily RPL554 (0.15, 0.5, 1.5, or 3 mg) or matching placebo via DPI.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.15 mg/Part A</title>
          <description>Part A: Single dose of RPL554 via DPI (double-blind).</description>
        </group>
        <group group_id="P2">
          <title>0.50 mg/Part A</title>
          <description>Part A: Single dose of RPL554 via DPI (double-blind).</description>
        </group>
        <group group_id="P3">
          <title>1.5 mg/Part A</title>
          <description>Part A: Single dose of RPL554 via DPI (double-blind).</description>
        </group>
        <group group_id="P4">
          <title>3 mg/Part A</title>
          <description>Part A: Single dose of RPL554 via DPI (double-blind).</description>
        </group>
        <group group_id="P5">
          <title>6 mg/Part A</title>
          <description>Part A: Single dose of RPL554 via DPI (single-blind). Part B: dose not used.</description>
        </group>
        <group group_id="P6">
          <title>Placebo/Part A</title>
          <description>Part A: Single dose via DPI (double-blind).</description>
        </group>
        <group group_id="P7">
          <title>Seq. 1/Part B</title>
          <description>Part B: 7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over.&#xD;
Seq 1 = RPL554 .15 mg/1.5 mg/3.0 mg/.50 mg/Placebo.</description>
        </group>
        <group group_id="P8">
          <title>Seq. 2/Part B</title>
          <description>Part B: 7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over.&#xD;
Seq 2 = RPL554 .15 mg/3.0 mg/Placebo/.50 mg/1.5 mg.</description>
        </group>
        <group group_id="P9">
          <title>Seq. 3/Part B</title>
          <description>Part B: 7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over.&#xD;
Seq 3 = RPL554 .50 mg/3.0 mg/.15 mg/Placebo/1.5 mg.</description>
        </group>
        <group group_id="P10">
          <title>Seq. 4/Part B</title>
          <description>Part B: 7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over.&#xD;
Seq 4 = RPL554 .50 mg/.15 mg/1.5 mg/Placebo/3.0 mg.</description>
        </group>
        <group group_id="P11">
          <title>Seq. 5/Part B</title>
          <description>Part B: 7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over.&#xD;
Seq 5 = RPL554 1.5 mg/.50 mg/Placebo/3.0 mg/.15 mg.</description>
        </group>
        <group group_id="P12">
          <title>Seq. 6/Part B</title>
          <description>Part B: 7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over.&#xD;
Seq 6 = RPL554 1.5 mg/Placebo/.15 mg/3.0 mg/.50 mg.</description>
        </group>
        <group group_id="P13">
          <title>Seq. 7/Part B</title>
          <description>Part B: 7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over.&#xD;
Seq 7 = RPL554 3.0 mg/1.5 mg/.50 mg/.15 mg/Placebo.</description>
        </group>
        <group group_id="P14">
          <title>Seq. 8/Part B</title>
          <description>Part B: 7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over.&#xD;
Seq 8 = RPL554 3.0 mg/Placebo/1.5 mg/.15 mg/.50 mg.</description>
        </group>
        <group group_id="P15">
          <title>Seq. 9/Part B</title>
          <description>Part B: 7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over.&#xD;
Seq 9 = Placebo/.15 mg/.50 mg/1.5 mg/3.0 mg.</description>
        </group>
        <group group_id="P16">
          <title>Seq. 10/Part B</title>
          <description>Part B: 7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over.&#xD;
Seq 10 = Placebo/.50 mg/3.0 mg/1.5 mg/.15 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A (R, PC, PG) Single Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B (R, PC, CO) Twice Daily for 7 Day</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="4"/>
                <participants group_id="P16" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="1">1 patient discontinued in part b/period 2 and another in part b/period 3.</participants>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="4"/>
                <participants group_id="P16" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.15 mg</title>
          <description>Single dose of RPL554 via DPI (double-blind)</description>
        </group>
        <group group_id="B2">
          <title>0.50 mg</title>
          <description>Single dose of RPL554 via DPI (double blind)</description>
        </group>
        <group group_id="B3">
          <title>1.5 mg</title>
          <description>Single dose of RPL554 via DPI (double blind)</description>
        </group>
        <group group_id="B4">
          <title>3 mg</title>
          <description>Single dose of RPL554 via DPI (double blind)</description>
        </group>
        <group group_id="B5">
          <title>6 mg</title>
          <description>Single dose of RPL554 via DPI (single blind)</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Single dose via DPI (double blind)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.7" spread="10.15"/>
                    <measurement group_id="B2" value="58.3" spread="3.56"/>
                    <measurement group_id="B3" value="63.7" spread="6.68"/>
                    <measurement group_id="B4" value="52.7" spread="3.88"/>
                    <measurement group_id="B5" value="59.3" spread="7.81"/>
                    <measurement group_id="B6" value="60.8" spread="8.80"/>
                    <measurement group_id="B7" value="59.5" spread="7.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12)</title>
        <description>RPL554 Plasma pharmacokinetics AUC0-12 (Area under the Curve) after single dose</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set in Part A: all randomized patients who had blood sampling performed after the single dose of RPL554 and had evaluable PK parameter data. The PK Analysis Set included the 31 patients who received RPL554 in Part A but not the 6 patients in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>Single dose of RPL554 via DPI (double-blind)</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O5">
            <title>6 mg</title>
            <description>Single dose of RPL554 via DPI (single blind)</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12)</title>
          <description>RPL554 Plasma pharmacokinetics AUC0-12 (Area under the Curve) after single dose</description>
          <population>Pharmacokinetic (PK) Analysis Set in Part A: all randomized patients who had blood sampling performed after the single dose of RPL554 and had evaluable PK parameter data. The PK Analysis Set included the 31 patients who received RPL554 in Part A but not the 6 patients in the placebo group.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260" spread="53.5"/>
                    <measurement group_id="O2" value="472" spread="106.7"/>
                    <measurement group_id="O3" value="2210" spread="62.3"/>
                    <measurement group_id="O4" value="4160" spread="47.2"/>
                    <measurement group_id="O5" value="9730" spread="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t)</title>
        <description>RPL554 Area under the curve at maximum concentration after a single dose</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set in Part A: all randomized patients who had blood sampling performed after the single dose of RPL554 and had evaluable PK parameter data. The PK Analysis Set included the 31 patients who received RPL554 in Part A but not the 6 patients in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>Single dose of RPL554 via DPI (double-blind)</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O5">
            <title>6 mg</title>
            <description>Single dose of RPL554 via DPI (single blind)</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t)</title>
          <description>RPL554 Area under the curve at maximum concentration after a single dose</description>
          <population>Pharmacokinetic (PK) Analysis Set in Part A: all randomized patients who had blood sampling performed after the single dose of RPL554 and had evaluable PK parameter data. The PK Analysis Set included the 31 patients who received RPL554 in Part A but not the 6 patients in the placebo group.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222" spread="55.5"/>
                    <measurement group_id="O2" value="495" spread="128.2"/>
                    <measurement group_id="O3" value="2680" spread="56.5"/>
                    <measurement group_id="O4" value="4920" spread="44.5"/>
                    <measurement group_id="O5" value="11600" spread="68.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life)</title>
        <description>RPL554 Plasma pharmacokinetics Half-life concentration after a single dose</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set in Part A: all randomized patients who had blood sampling performed after the single dose of RPL554 and had evaluable PK parameter data. The PK Analysis Set included the 31 patients who received RPL554 in Part A but not the 6 patients in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>Single dose of RPL554 via DPI (double-blind)</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O5">
            <title>6 mg</title>
            <description>Single dose of RPL554 via DPI (single blind)</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life)</title>
          <description>RPL554 Plasma pharmacokinetics Half-life concentration after a single dose</description>
          <population>Pharmacokinetic (PK) Analysis Set in Part A: all randomized patients who had blood sampling performed after the single dose of RPL554 and had evaluable PK parameter data. The PK Analysis Set included the 31 patients who received RPL554 in Part A but not the 6 patients in the placebo group.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59"/>
                    <measurement group_id="O2" value="5.39" spread="28.7"/>
                    <measurement group_id="O3" value="7.48" spread="43.3"/>
                    <measurement group_id="O4" value="6.65" spread="33.6"/>
                    <measurement group_id="O5" value="6.66" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)</title>
        <description>Change from Baseline FEV1 to Peak FEV1 (over 4 hours) on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>7 day, twice daily dose of placebo via DPI (double-blind) complete block, cross-over</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)</title>
          <description>Change from Baseline FEV1 to Peak FEV1 (over 4 hours) on Day 7</description>
          <population>All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.220" spread="0.1593"/>
                    <measurement group_id="O2" value="0.293" spread="0.2411"/>
                    <measurement group_id="O3" value="0.298" spread="0.2355"/>
                    <measurement group_id="O4" value="0.378" spread="0.2182"/>
                    <measurement group_id="O5" value="0.118" spread="0.1437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.186</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.138</ci_lower_limit>
            <ci_upper_limit>1.235</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.134</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.088</ci_lower_limit>
            <ci_upper_limit>1.181</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.134</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.089</ci_lower_limit>
            <ci_upper_limit>1.181</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.084</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.041</ci_lower_limit>
            <ci_upper_limit>1.128</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Change From Baseline in Average FEV1 (Over 4 Hours)</title>
        <description>Change from Baseline FEV1 to Average FEV1 (over 4 hours) After Single Dose</description>
        <time_frame>Day 1</time_frame>
        <population>Full Analysis Set (FAS) in Part A: all randomized patients with sufficient data collected after intake of study medication to compute the PD parameters (FEV1 measurements pre dose and at least 1 post-baseline). All 37 patients randomized into Part A were included in the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>Single dose of RPL554 via DPI (double-blind)</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O5">
            <title>6 mg</title>
            <description>Single dose of RPL554 via DPI (single blind)</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Single dose via DPI (double blind)</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Average FEV1 (Over 4 Hours)</title>
          <description>Change from Baseline FEV1 to Average FEV1 (over 4 hours) After Single Dose</description>
          <population>Full Analysis Set (FAS) in Part A: all randomized patients with sufficient data collected after intake of study medication to compute the PD parameters (FEV1 measurements pre dose and at least 1 post-baseline). All 37 patients randomized into Part A were included in the FAS.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.109" spread="0.0380"/>
                    <measurement group_id="O2" value="0.213" spread="0.1226"/>
                    <measurement group_id="O3" value="0.326" spread="0.249"/>
                    <measurement group_id="O4" value="0.337" spread="0.1831"/>
                    <measurement group_id="O5" value="0.334" spread="0.1170"/>
                    <measurement group_id="O6" value="0.040" spread="0.0517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.228</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.105</ci_lower_limit>
            <ci_upper_limit>1.365</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.228</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.104</ci_lower_limit>
            <ci_upper_limit>1.365</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.196</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.080</ci_lower_limit>
            <ci_upper_limit>1.326</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0348</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.121</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.009</ci_lower_limit>
            <ci_upper_limit>1.246</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3106</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.055</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.949</ci_lower_limit>
            <ci_upper_limit>1.172</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Change From Baseline in Average FEV1 (Over 12 Hours)</title>
        <description>Change from Baseline FEV1 to Average FEV1 (over 12 hours) After Single Dose</description>
        <time_frame>Day 1</time_frame>
        <population>Full Analysis Set (FAS) in Part A: all randomized patients with sufficient data collected after intake of study medication to compute the PD parameters (FEV1 measurements pre dose and at least 1 post-baseline). All 37 patients randomized into Part A were included in the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>Single dose of RPL554 via DPI (double-blind)</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O5">
            <title>6 mg</title>
            <description>Single dose of RPL554 via DPI (single blind)</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Single dose via DPI (double blind)</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Average FEV1 (Over 12 Hours)</title>
          <description>Change from Baseline FEV1 to Average FEV1 (over 12 hours) After Single Dose</description>
          <population>Full Analysis Set (FAS) in Part A: all randomized patients with sufficient data collected after intake of study medication to compute the PD parameters (FEV1 measurements pre dose and at least 1 post-baseline). All 37 patients randomized into Part A were included in the FAS.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.045" spread="0.0384"/>
                    <measurement group_id="O2" value="0.113" spread="0.1703"/>
                    <measurement group_id="O3" value="0.214" spread="0.2172"/>
                    <measurement group_id="O4" value="0.243" spread="0.2715"/>
                    <measurement group_id="O5" value="0.176" spread="0.0481"/>
                    <measurement group_id="O6" value="-0.011" spread="0.0749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0208</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.154</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.024</ci_lower_limit>
            <ci_upper_limit>1.301</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0041</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.200</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.064</ci_lower_limit>
            <ci_upper_limit>1.353</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0108</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.167</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.039</ci_lower_limit>
            <ci_upper_limit>1.311</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1641</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.087</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.965</ci_lower_limit>
            <ci_upper_limit>1.225</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Change From Baseline in Peak FEV1 (Over 4 Hours)</title>
        <description>Change from Baseline FEV1 to Peak FEV1 (over 4 hours) After Single Dose</description>
        <time_frame>Day 1</time_frame>
        <population>Full Analysis Set (FAS) in Part A: all randomized patients with sufficient data collected after intake of study medication to compute the PD parameters (FEV1 measurements pre dose and at least 1 post-baseline). All 37 patients randomized into Part A were included in the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>Single dose of RPL554 via DPI (double-blind)</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>Single dose of RPL554 via DPI (double blind)</description>
          </group>
          <group group_id="O5">
            <title>6 mg</title>
            <description>Single dose of RPL554 via DPI (single blind)</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Single dose via DPI (double blind)</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Peak FEV1 (Over 4 Hours)</title>
          <description>Change from Baseline FEV1 to Peak FEV1 (over 4 hours) After Single Dose</description>
          <population>Full Analysis Set (FAS) in Part A: all randomized patients with sufficient data collected after intake of study medication to compute the PD parameters (FEV1 measurements pre dose and at least 1 post-baseline). All 37 patients randomized into Part A were included in the FAS.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.203" spread="0.0646"/>
                    <measurement group_id="O2" value="0.298" spread="0.1280"/>
                    <measurement group_id="O3" value="0.429" spread="0.2504"/>
                    <measurement group_id="O4" value="0.468" spread="0.2135"/>
                    <measurement group_id="O5" value="0.452" spread="0.1382"/>
                    <measurement group_id="O6" value="0.135" spread="0.0922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.229</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.102</ci_lower_limit>
            <ci_upper_limit>1.369</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.231</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.104</ci_lower_limit>
            <ci_upper_limit>1.372</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.188</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.070</ci_lower_limit>
            <ci_upper_limit>1.320</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0658</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.106</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.993</ci_lower_limit>
            <ci_upper_limit>1.233</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Safety and Tolerability / Hematology Safety Assessments</title>
        <description>number of patients with treatment-emergent hematology abnormal laboratory assessments</description>
        <time_frame>Day 1</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Safety and Tolerability / Blood Chemistry Safety Assessments</title>
        <description>number of patients with treatment-emergent blood chemistry abnormal laboratory assessments</description>
        <time_frame>Day 1</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Safety and Tolerability / Urinalysis Safety Assessments</title>
        <description>number of patients with treatment-emergent urinalysis abnormal laboratory assessments</description>
        <time_frame>Day 1</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Safety and Tolerability / Supine Vital Signs - Pulse Rate</title>
        <description>Change from Baseline Pulse Rate to Peak Pulse Rate (over 4 hours) After Single Dose</description>
        <time_frame>Day 1</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Safety and Tolerability / Supine Vital Signs - Blood Pressure</title>
        <description>number of patients with treatment-emergent abnormal vital signs (blood pressure in mm Hg) (An increase from baseline of &gt;=20 in systolic bp)</description>
        <time_frame>Day 1</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Safety and Tolerability / ECG - QTcF</title>
        <description>number of patients with treatment-emergent abnormal ECG parameters, QTcF in msec</description>
        <time_frame>Day 1</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Safety and Tolerability / ECG - Heart Rate</title>
        <description>number of patients with treatment-emergent clinically significant abnormal ECG parameters, heart rate in bpm</description>
        <time_frame>Day 1</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Average FEV1 (Over 4 Hrs)</title>
        <description>Change from baseline in average FEV1 (over 4 hours) on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>7 day, twice daily dose of placebo via DPI (double-blind) complete block, cross-over</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Average FEV1 (Over 4 Hrs)</title>
          <description>Change from baseline in average FEV1 (over 4 hours) on Day 7</description>
          <population>All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.100" spread="0.1430"/>
                    <measurement group_id="O2" value="0.176" spread="0.2253"/>
                    <measurement group_id="O3" value="0.184" spread="0.2176"/>
                    <measurement group_id="O4" value="0.244" spread="0.1953"/>
                    <measurement group_id="O5" value="0.017" spread="0.1526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.183</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.134</ci_lower_limit>
            <ci_upper_limit>1.234</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.140</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.092</ci_lower_limit>
            <ci_upper_limit>1.190</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.131</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.084</ci_lower_limit>
            <ci_upper_limit>1.180</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.080</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.036</ci_lower_limit>
            <ci_upper_limit>1.126</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Average FEV1 (Over 12 Hours)</title>
        <description>Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>7 day, twice daily dose of placebo via DPI (double-blind) complete block, cross-over</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Average FEV1 (Over 12 Hours)</title>
          <description>Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 7</description>
          <population>All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.052" spread="0.1759"/>
                    <measurement group_id="O2" value="0.106" spread="0.2125"/>
                    <measurement group_id="O3" value="0.096" spread="0.1796"/>
                    <measurement group_id="O4" value="0.163" spread="0.1679"/>
                    <measurement group_id="O5" value="0.016" spread="0.1455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.123</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.078</ci_lower_limit>
            <ci_upper_limit>1.169</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.078</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.035</ci_lower_limit>
            <ci_upper_limit>1.122</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.081</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.039</ci_lower_limit>
            <ci_upper_limit>1.125</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0437</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.041</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.001</ci_lower_limit>
            <ci_upper_limit>1.083</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Trough FEV1</title>
        <description>Change from Baseline FEV1 to Morning Trough FEV1 on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>7 day, twice daily dose of placebo via DPI (double-blind) complete block, cross-over</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Trough FEV1</title>
          <description>Change from Baseline FEV1 to Morning Trough FEV1 on Day 7</description>
          <population>All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.036" spread="0.1332"/>
                    <measurement group_id="O2" value="0.031" spread="0.1821"/>
                    <measurement group_id="O3" value="0.020" spread="0.1838"/>
                    <measurement group_id="O4" value="0.030" spread="0.1539"/>
                    <measurement group_id="O5" value="-0.067" spread="0.1577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.087</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.038</ci_lower_limit>
            <ci_upper_limit>1.139</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.083</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.034</ci_lower_limit>
            <ci_upper_limit>1.135</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.096</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.047</ci_lower_limit>
            <ci_upper_limit>1.149</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0971</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.039</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.993</ci_lower_limit>
            <ci_upper_limit>1.088</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)</title>
        <description>Change from baseline FEV1 in peak FEV1 (over 4 hours) after first dose</description>
        <time_frame>Day 1</time_frame>
        <population>All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>7 day, twice daily dose of placebo via DPI (double-blind) complete block, cross-over</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)</title>
          <description>Change from baseline FEV1 in peak FEV1 (over 4 hours) after first dose</description>
          <population>All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.310" spread="0.1382"/>
                    <measurement group_id="O2" value="0.332" spread="0.2181"/>
                    <measurement group_id="O3" value="0.401" spread="0.1705"/>
                    <measurement group_id="O4" value="0.404" spread="0.1867"/>
                    <measurement group_id="O5" value="0.188" spread="0.1267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.145</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.106</ci_lower_limit>
            <ci_upper_limit>1.185</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.148</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.109</ci_lower_limit>
            <ci_upper_limit>1.189</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.099</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.062</ci_lower_limit>
            <ci_upper_limit>1.137</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.088</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.052</ci_lower_limit>
            <ci_upper_limit>1.126</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Average FEV1 (Over 4 Hours)</title>
        <description>Change from baseline FEV1 in average FEV1 (over 4 hours) on Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>7 day, twice daily dose of placebo via DPI (double-blind) complete block, cross-over</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Average FEV1 (Over 4 Hours)</title>
          <description>Change from baseline FEV1 in average FEV1 (over 4 hours) on Day 1</description>
          <population>All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.201" spread="0.1180"/>
                    <measurement group_id="O2" value="0.227" spread="0.2026"/>
                    <measurement group_id="O3" value="0.268" spread="0.1518"/>
                    <measurement group_id="O4" value="0.285" spread="0.1597"/>
                    <measurement group_id="O5" value="0.079" spread="0.1081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.150</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.113</ci_lower_limit>
            <ci_upper_limit>1.189</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.146</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.109</ci_lower_limit>
            <ci_upper_limit>1.185</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.107</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.071</ci_lower_limit>
            <ci_upper_limit>1.144</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.094</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.059</ci_lower_limit>
            <ci_upper_limit>1.130</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Average FEV1 (Over 12 Hours)</title>
        <description>Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>7 day, twice daily dose of placebo via DPI (double-blind) complete block, cross-over</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Average FEV1 (Over 12 Hours)</title>
          <description>Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 1</description>
          <population>All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.101" spread="0.1314"/>
                    <measurement group_id="O2" value="0.139" spread="0.1921"/>
                    <measurement group_id="O3" value="0.135" spread="0.1655"/>
                    <measurement group_id="O4" value="0.182" spread="0.1536"/>
                    <measurement group_id="O5" value="0.044" spread="0.1073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.103</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.066</ci_lower_limit>
            <ci_upper_limit>1.141</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.078</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.042</ci_lower_limit>
            <ci_upper_limit>1.116</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.067</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.032</ci_lower_limit>
            <ci_upper_limit>1.104</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0066</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast Ratio</param_type>
            <param_value>1.048</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.013</ci_lower_limit>
            <ci_upper_limit>1.084</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action)</title>
        <description>Determination of onset of action (&gt;10% increase in FEV1 from pre- to post-first dose, censored at 120 minutes) on Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set in Part B: all randomized patients who had blood sampling performed after at least 1 dose of RPL554 in Part B and with data sufficient to calculate PK parameters. The PK analysis set comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action)</title>
          <description>Determination of onset of action (&gt;10% increase in FEV1 from pre- to post-first dose, censored at 120 minutes) on Day 1</description>
          <population>Pharmacokinetic (PK) Analysis Set in Part B: all randomized patients who had blood sampling performed after at least 1 dose of RPL554 in Part B and with data sufficient to calculate PK parameters. The PK analysis set comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
          <units>mins</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="3" upper_limit="120"/>
                    <measurement group_id="O2" value="15" lower_limit="3" upper_limit="120"/>
                    <measurement group_id="O3" value="15" lower_limit="4" upper_limit="125"/>
                    <measurement group_id="O4" value="13" lower_limit="4" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Safety and Tolerability / Hematology Safety Assessments</title>
        <description>number of patients with treatment-emergent hematology abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 or at the end of study in &gt;3 patients in each treatment group).</description>
        <time_frame>Day 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Safety and Tolerability / Blood Chemistry Safety Assessments</title>
        <description>number of patients with treatment-emergent blood chemistry abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 in each treatment group).</description>
        <time_frame>Day 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Safety and Tolerability / Urinalysis Safety Assessments</title>
        <description>number of patients with treatment-emergent urinalysis abnormal laboratory assessments</description>
        <time_frame>Day 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Safety and Tolerability / ECG - QTcF</title>
        <description>number of patients with treatment-emergent clinically significant abnormal ECG parameters, QTcF in msec</description>
        <time_frame>Day 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Safety and Tolerability / ECG - Heart Rate</title>
        <description>number of patients with treatment-emergent abnormal ECG parameters, heart rate in bpm</description>
        <time_frame>Day 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Safety and Tolerability / Supine Vital Signs - Pulse Rate</title>
        <description>number of patients with treatment-emergent abnormal vital signs (pulse rate in bpm) An increase from baseline of &gt;=20</description>
        <time_frame>Day 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Safety and Tolerability / Supine Vital Signs - Blood Pressure</title>
        <description>number of patients with treatment-emergent abnormal vital signs (systolic blood pressure in mm Hg) (An increase from baseline of &gt;=20)</description>
        <time_frame>Day 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Peak Pulse Rate (Day 1)</title>
        <description>Change from baseline in peak pulse after first dose on Day 1</description>
        <time_frame>Day 1</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Peak Pulse Rate (Day 7)</title>
        <description>Change from baseline in peak pulse after morning dosing on Day 7</description>
        <time_frame>Day 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: RPL554 Plasma Pharmacokinetic Parameter (Tmax)</title>
        <description>RPL554 steady-state PK (tmax) after morning dose on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set in Part B: all randomized patients who had blood sampling performed after at least 1 dose of RPL554 in Part B and with data sufficient to calculate PK parameters. The PK analysis set comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: RPL554 Plasma Pharmacokinetic Parameter (Tmax)</title>
          <description>RPL554 steady-state PK (tmax) after morning dose on Day 7</description>
          <population>Pharmacokinetic (PK) Analysis Set in Part B: all randomized patients who had blood sampling performed after at least 1 dose of RPL554 in Part B and with data sufficient to calculate PK parameters. The PK analysis set comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.417" upper_limit="2.000"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.000" upper_limit="3.917"/>
                    <measurement group_id="O3" value="1.000" lower_limit="0.000" upper_limit="2.000"/>
                    <measurement group_id="O4" value="1.000" lower_limit="0.000" upper_limit="2.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: RPL554 Plasma Pharmacokinetic Parameter (Cmax)</title>
        <description>RPL554 steady-state PK (Cmax and accumulation ratio) after morning dose on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set in Part B: all randomized patients who had blood sampling performed after at least 1 dose of RPL554 in Part B and with data sufficient to calculate PK parameters. The PK analysis set comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: RPL554 Plasma Pharmacokinetic Parameter (Cmax)</title>
          <description>RPL554 steady-state PK (Cmax and accumulation ratio) after morning dose on Day 7</description>
          <population>Pharmacokinetic (PK) Analysis Set in Part B: all randomized patients who had blood sampling performed after at least 1 dose of RPL554 in Part B and with data sufficient to calculate PK parameters. The PK analysis set comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7" spread="41.6"/>
                    <measurement group_id="O2" value="237" spread="47.4"/>
                    <measurement group_id="O3" value="591" spread="71.1"/>
                    <measurement group_id="O4" value="1240" spread="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h)</title>
        <description>RPL554 steady-state PK (AUC0-12h and accumulation ratio) after morning dose on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set in Part B: all randomized patients who had blood sampling performed after at least 1 dose of RPL554 in Part B and with data sufficient to calculate PK parameters. The PK analysis set comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
        <group_list>
          <group group_id="O1">
            <title>0.15 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O2">
            <title>0.50 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
          <group group_id="O4">
            <title>3 mg</title>
            <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h)</title>
          <description>RPL554 steady-state PK (AUC0-12h and accumulation ratio) after morning dose on Day 7</description>
          <population>Pharmacokinetic (PK) Analysis Set in Part B: all randomized patients who had blood sampling performed after at least 1 dose of RPL554 in Part B and with data sufficient to calculate PK parameters. The PK analysis set comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263" spread="56.2"/>
                    <measurement group_id="O2" value="1240" spread="52.3"/>
                    <measurement group_id="O3" value="3070" spread="73.6"/>
                    <measurement group_id="O4" value="6460" spread="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Part A: 24 hours. Part B: Approximately 70 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part A: 0.15 mg</title>
          <description>Single dose of RPL554 via DPI (double-blind)</description>
        </group>
        <group group_id="E2">
          <title>Part A: 0.50 mg</title>
          <description>Single dose of RPL554 via DPI (double blind)</description>
        </group>
        <group group_id="E3">
          <title>Part A: 1.5 mg</title>
          <description>Single dose of RPL554 via DPI (double blind)</description>
        </group>
        <group group_id="E4">
          <title>Part A: 3 mg</title>
          <description>Single dose of RPL554 via DPI (double blind)</description>
        </group>
        <group group_id="E5">
          <title>Part A: 6 mg</title>
          <description>Single dose of RPL554 via DPI (single blind)</description>
        </group>
        <group group_id="E6">
          <title>Part A: Placebo</title>
          <description>Single dose of placebo via DPI (double blind)</description>
        </group>
        <group group_id="E7">
          <title>Part B: 0.15 mg</title>
          <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
        </group>
        <group group_id="E8">
          <title>Part B: 0.50 mg</title>
          <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
        </group>
        <group group_id="E9">
          <title>Part B: 1.5 mg</title>
          <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
        </group>
        <group group_id="E10">
          <title>Part B: 3 mg</title>
          <description>7 day, twice daily dose of RPL554 via DPI (double-blind) complete block, cross-over</description>
        </group>
        <group group_id="E11">
          <title>Part B: Placebo</title>
          <description>7 day, twice daily dose of placebo via DPI (double-blind) complete block, cross-over</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Eye contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Verona Pharma</name_or_title>
      <organization>Verona Pharma</organization>
      <phone>+44 (0)203 283 4200</phone>
      <email>info@veronapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

